NCT07210528 · Phase 1 · ACTIVE NOT RECRUITING
Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study
This trial tests whether two existing HIV drugs, emtricitabine alone or Descovy, are safe and well tolerated over 3 months in people with mild cognitive impairment. It also takes an early look at memory and thinking tests and inflammation markers. It is a Phase 1 trial, which means an early safety check, not proof that it works.
You may qualify if
- CDR-GS of 0 or 0.5 (calculated by the QDRS)
- Diagnosed with MCI, determined by impairment in at least one domain of the neuropsychological test battery without significant dysfunction in activities of daily living OR MCI consistent with the NIA/AA diagnostic criteria; OR presenting with SCD and a CDR-GS of 0.5.
- Does not have any medical condition (e.g. cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments.
- Willingness to provide blood sample and neuropsychological testing for the study.
- Ability for the patient to provide informed consent.
You're excluded if
- Patient who is receiving a prescription of acetylcholinesterase inhibitor (AChEI) and/or Memantine at screening or baseline.
- Patients with a history of HIV or HBV infection, or that test positive for HIV or HBV on screening.
- Pre-existing comorbidities such as Hepatits, cardiovascular disease, or renal insufficiency.
- History of Moderate to severe hepatic impairment indicated by screening AST or ALT > 3x the upper limit of normal (ULN) or total bilirubin > 2x ULN.
- Patients with severe renal impairment, or creatinine clearance ≤ 30 mL/min (calculated by Cockcroft-Gault formulae at screening).
- Co administration of nephrotoxic drugs.
- Current or previous RTi use within the last 2 years.
- Malignant neoplasm, and are undergoing active treatment.
- Participating in other interventional clinical trials during the course of the study.
- Documented history of lactic acidosis and severe hepatomegaly with steatosis.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-10